Dupixent COPD Approval Could Be Delayed, Regeneron Cautions

 
• By Jessica Merrill

The US Food and Drug Administration has requested additional efficacy information on the supplemental filing in the potentially large new indication.

hour glass
Regeneron signaled a possible delay for Dupixent in COPD • Source: Shutterstock

More from Immunological

More from Therapy Areas